Summit Therapeutics (SUMM)
09/01/2018 - 12:00 RNS
Summit Therapeutics to Present at the Biotech Showcase Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT THE BIOTECH SHOWCASE Oxford, UK, 9 January 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for rare diseases ...
27/12/2017 - 08:44 StockMarketWire
Summit Therapeutics is to pay 10m in cash and shares for Discuva whose principal asset is a genetics-based technology plat...
27/12/2017 - 07:00 RNS
RNS Number: 2793A Summit Therapeutics PLC 27 December 2017 Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT OBTAINS INNOVATIVE ANTIBIOTIC DISCOVERY AND DEVELOPMENT PLATFORM THROUGH ACQUISITION OF DISCUVA LTD Positions Summit as a Leader in Research & Development of New Classes of Antibiotics En...
21/12/2017 - 09:20 StockMarketWire
Summit Therapeutics, a drug discovery and development company, has entered into an exclusive licence and commerciali...
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment